Circulating Levels of PAI-1 and SERPINE1 4G/4G Polymorphism Are Predictive of Poor Prognosis in HCC Patients Undergoing TACE
Open Access
- 1 August 2015
- journal article
- Published by Elsevier in Translational Oncology
- Vol. 8 (4) , 273-278
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Combination Trans Arterial Chemoembolization (TACE) Plus Sorafenib for the Management of Unresectable Hepatocellular Carcinoma: A Systematic Review of the LiteratureDigestive Diseases and Sciences, 2013
- Genome-wide association study for circulating levels of PAI-1 provides novel insights into its regulationBlood, 2012
- The Biochemistry, Physiology and Pathological roles of PAI-1 and the requirements for PAI-1 inhibition in vivoThrombosis Research, 2012
- Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1Expert Review of Molecular Diagnostics, 2010
- Prognostic value of pre-surgical plasma PAI-1 (plasminogen activator inhibitor-1) levels in breast cancerThrombosis Research, 2009
- Biochemical properties of plasminogen activator inhibitor-1Frontiers in Bioscience-Landmark, 2009
- Genetic Architecture of Tissue-Type Plasminogen Activator and Plasminogen Activator Inhibitor-1Seminars in Thrombosis and Hemostasis, 2008
- PAI-1 gene 4G/5G polymorphism, cytokine levels and their relations with metabolic parameters in obese childrenThrombosis and Haemostasis, 2008
- Promoter (4G/5G) Plasminogen Activator Inhibitor-1 Genotype and Plasminogen Activator Inhibitor-1 Levels in Blacks, Hispanics, and Non-Hispanic WhitesCirculation, 2003
- Plasminogen-Activator Inhibitor Type 1 and Coronary Artery DiseaseNew England Journal of Medicine, 2000